Impact of local treatment modality on overall‐ and disease‐specific survival for nonmetastatic pelvic and sacral Ewing sarcoma. Issue 3 (18th May 2022)

• Record Type: Journal Article
• Authors: Jawad, Muhammad Umar; Pollock, Brad H.; Zeitlinger, Lauren N.; O'Donnell, Edmond F.; Traven, Sophia A.; Carr‐Ascher, Janai R.; Alvarez, Elysia; Malogolowkin, Marcio H.; Thorpe, Steven W.; Randall, R. Lor
• Is Part Of: Journal of surgical oncology. Volume 126:Issue 3(2022)
• Page Start: 577
• Page End: 587
• Publication Date: 2022-05-18
• Subjects: Ewing sarcoma -- pelvis -- radiotherapy -- sacrum -- surgery; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26922
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Purpose: The ideal local treatment modality for pelvic and sacral Ewing sarcoma (EWS) is controversial. Methods: We present the data from the American College of Surgeon's National Cancer Database (NCDB) and the National Cancer Institute's Surveillance, Epidemiology and End Result (SEER) database to investigate the impact of local treatment modalities on survival for nonmetastatic pelvic and sacral Ewing sarcoma. Local treatment includes "surgery, " "radiation, " and a combination of "surgery and radiation." Results: A total of 235 cases from SEER and 285 cases from NCDB were analyzed. Patients with "localized" stage (intraosseous) in the SEER database did not show any statistically significant difference in the disease‐specific survival (DSS) for any of the local treatment modalities. Similar findings were observed for overall survival among patients with American Joint Committee on Cancer (AJCC) stage II and III in the NCDB database. However, patients with nonmetastatic disease, particularly regional disease (extraosseous), showed improved DSS with surgery only, in the SEER. Conclusion: We found similar levels of efficacy for different treatment modalities for patients with intraosseous and AJCC II and III pelvic and sacral EWS. "Radiotherapy" is the most common local treatment modality employed in the United States. A prospective, randomized controlled trial with a direct head‐to‐head comparison is needed for a definitive conclusion.